Novocure Ltd.'s U.S. subsidiary, Novocure Inc., recently received notice from the Centers for Medicare & Medicaid Services $(CMS)$ that its billing privileges for its products were revoked retroactive to December 17, 2025. The revocation was due to an administrative process issue related to the triannual re-validation process. Novocure Inc. has filed a Corrective Action Plan with CMS and expects billing privileges to be reinstated, but the timing remains uncertain. During this period, Novocure Inc. continues to provide services to existing and new patients but cannot bill CMS payors for services rendered since the revocation date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novocure Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001645113-26-000007), on February 05, 2026, and is solely responsible for the information contained therein.